AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout
Ämnen: Farmaci
-
-
Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .
-
AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer
-
AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca
-
STUDIE VISAR ATT ”MOBIL-APP” FÖRBÄTTRADE FÖLJSAMHET TILL BEHANDLING EFTER HJÄRTINFARKT
Resultaten från den svenska SUPPORT-studien, som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt med hjälp av en mobiltelefonapplikation, publiceras nu i American Heart Journal. Studien visar att de patienter som fick ett interaktivt patientverktyg i form av en ”mobil-app” i högre grad tog sitt blodproppshämmande läkemedel ticagrelor enligt läkarens ordination.
-
AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016 - Leadership in DNA damage response therapies
73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour types Continued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation, and new data in first-line NSCLC
-
AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer
AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.
-
AstraZeneca tillkännager positiva resultat från fas III-studier med benralizumab vid behandling av svår astma
Benralizumab är AstraZenecas första biologiska läkemedel för sjukdomar i andningsvägarna som slutfört studier i fas III
-
AstraZeneca to highlight the breadth of its respiratory medicines at American Thoracic Society 2016 International Conference
New data reflect advancements across novel inhaled therapies, respiratory biologics and research into underlying disease pathways
-
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
-
Positive CHMP opinion for CAZ AVI in the EU for serious bacterial infections
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of a new antibiotic, CAZ AVI 2g/0.5g powder.
-
AstraZeneca PLC’s resultatrapport för första kvartalet 2016
Ekonomisk sammanfattning
MUSD Ändring i % i fasta valutakurser1 Utfall Totala intäkter2 6 115 5 1 Rörelseresultat för kärnverksamheten 3 1 593 (8) (12) Vinst per aktie för kärnverksamheten (Core EPS) $0,95 (7) (12) Redovisat rörelseresultat 1 038 17 11 Redovisad vinst per aktie $0,51 26 17
De total -
AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad
AstraZeneca today announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout.
-
Bevespi Aerosphere har godkänts av FDA för patienter med KOL
Visar på tydlig förbättring i lungfunktion jämfört med monokomponenter och placebo
Den enda långtidsverkande dubbla luftrörsvidgaren som kommer i en dosaerosol (pMDI) och den första produkten med AstraZenecas patenterade Co-Suspension Technology
AstraZeneca meddelar idag att amerikanska Food and Drug Administration har godkänt Bevespi Aerosphere (glykopyrrolat och formoterolfumarat),en inhal -
AstraZeneca lanserar integrerat forskningsinitiativ inom genomik som kommer ändra vårt sätt att jobba med upptäckt och utveckling av läkemedel
AstraZeneca och MedImmune, koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, meddelar idag ett integrerat forskningsinititativ inom genomik som kommer att ändra vårt sätt att arbeta för att upptäcka och utveckla läkemedel tvärsöver hela forsknings- och utvecklingsportföljen
-
ASTRAZENECA PRESENTS POSITIVE TAGRISSO (OSIMERTINIB) FOLLOW-UP DATA IN LUNG CANCER AT ELCC 2016
Phase I first-line Tagrisso (osimertinib) data show an objective response rate of 77%, and progression-free survival of 19.3 months in patients with EGFRm NSCLC1 Updated results in pre-treated patients with EGFR T790M mutation-positive NSCLC further support recent approvals in the US, EU and Japan
-
AstraZeneca showcases breadth of oncology portfolio at AACR 2016 Annual Meeting
More than 60 presentations featuring 26 potential medicines across four key scientific platforms, including DNA Damage Response (DDR) and Immuno-Oncolog
-
AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease
Phase II/III trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase III after positive interim safety data
-
AstraZeneca to showcase clinical and scientific leadership in lung cancer at ELCC 2016
Tagrisso™ late-breaker presentations provide updated data in first-line EGFRm and second-line EGFRm T790M lung cancer
Studies demonstrate use of blood based testing to identify patients for treatment with Iressa and Tagrisso
Data from exploratory immuno-oncology and small molecule combination studies to be presented during the conference
AstraZeneca and its global biologics research and -
Pandemic influenza vaccine receives positive CHMP opinion
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional approval of Pandemic Live Attenuated Influenza Vaccine (P/LAIV). P/LAIV is indicated for the prevention of influenza in an officially declared pa
Visa mer
Loading...